Bridgewater Associates LP lifted its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 11.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,772 shares of the biopharmaceutical company’s stock after buying an additional 1,273 shares during the quarter. Bridgewater Associates LP’s holdings in Regeneron Pharmaceuticals were worth $5,160,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently modified their holdings of REGN. FMR LLC increased its position in Regeneron Pharmaceuticals by 17.0% during the third quarter. FMR LLC now owns 5,016,501 shares of the biopharmaceutical company’s stock worth $2,026,867,000 after acquiring an additional 728,104 shares during the period. Alliancebernstein L.P. increased its position in Regeneron Pharmaceuticals by 35.8% during the third quarter. Alliancebernstein L.P. now owns 1,023,594 shares of the biopharmaceutical company’s stock worth $413,573,000 after acquiring an additional 269,696 shares during the period. Ffcm LLC increased its position in Regeneron Pharmaceuticals by 27,119.4% during the third quarter. Ffcm LLC now owns 256,407 shares of the biopharmaceutical company’s stock worth $11,599,000 after acquiring an additional 255,465 shares during the period. Janus Henderson Group PLC increased its position in Regeneron Pharmaceuticals by 12.7% during the second quarter. Janus Henderson Group PLC now owns 1,802,740 shares of the biopharmaceutical company’s stock worth $621,927,000 after acquiring an additional 203,306 shares during the period. Finally, Candriam Luxembourg S.C.A. increased its position in Regeneron Pharmaceuticals by 83.7% during the third quarter. Candriam Luxembourg S.C.A. now owns 346,383 shares of the biopharmaceutical company’s stock worth $139,953,000 after acquiring an additional 157,800 shares during the period. Institutional investors and hedge funds own 66.83% of the company’s stock.
In other news, major shareholder Sanofi sold 104,552 shares of the business’s stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $406.68, for a total value of $42,519,207.36. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Joseph L. Goldstein sold 2,000 shares of the business’s stock in a transaction on Monday, September 24th. The shares were sold at an average price of $388.65, for a total transaction of $777,300.00. Following the completion of the sale, the director now owns 13,000 shares in the company, valued at approximately $5,052,450. The disclosure for this sale can be found here. Insiders sold a total of 108,552 shares of company stock worth $44,081,027 in the last 90 days. 12.42% of the stock is owned by corporate insiders.
Shares of Regeneron Pharmaceuticals stock opened at $365.65 on Monday. The firm has a market capitalization of $39.57 billion, a price-to-earnings ratio of 27.27, a price-to-earnings-growth ratio of 1.57 and a beta of 1.34. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.30 and a current ratio of 4.04. Regeneron Pharmaceuticals Inc has a 52-week low of $281.89 and a 52-week high of $416.49.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $4.94 by $0.93. Regeneron Pharmaceuticals had a net margin of 28.24% and a return on equity of 30.24%. The firm had revenue of $1.66 billion for the quarter, compared to analyst estimates of $1.64 billion. During the same quarter in the previous year, the firm posted $3.99 EPS. The business’s revenue for the quarter was up 10.8% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals Inc will post 19.48 EPS for the current fiscal year.
A number of equities analysts recently issued reports on REGN shares. Barclays boosted their target price on shares of Regeneron Pharmaceuticals from $290.00 to $305.00 and gave the stock an “underweight” rating in a research report on Monday, August 6th. BidaskClub lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 11th. Cowen reaffirmed a “hold” rating and set a $385.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, August 16th. ValuEngine raised shares of Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 6th. Finally, Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a research report on Monday, October 1st. They set a “neutral” rating and a $415.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, seventeen have given a hold rating and five have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $402.37.
TRADEMARK VIOLATION NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2018/12/03/bridgewater-associates-lp-has-5-16-million-stake-in-regeneron-pharmaceuticals-inc-regn.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Article: Price to Earnings Ratio (PE) Basics
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.